U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. VYJUVEK
  1. Vaccines, Blood & Biologics

STN: 125774
Proper Name: beremagene geperpavec
Tradename: VYJUVEK
Manufacturer: Krystal Biotech, Inc.
Indication:

  • For the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

Product Information

  • Package Insert - VYJUVEK
  • Demographic Subgroup Information – VYJUVEK
    Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Supporting Documents

 

Back to Top